Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2–p53 Interaction

Citations Over TimeTop 20% of 2014 papers

Abstract

Structure-based rational design and extensive structure-activity relationship studies led to the discovery of AMG 232 (1), a potent piperidinone inhibitor of the MDM2-p53 association, which is currently being evaluated in human clinical trials for the treatment of cancer. Further modifications of 1, including replacing the carboxylic acid with a 4-amidobenzoic acid, afforded AM-7209 (25), featuring improved potency (KD from ITC competition was 38 pM, SJSA-1 EdU IC50 = 1.6 nM), remarkable pharmacokinetic properties, and in vivo antitumor activity in both the SJSA-1 osteosarcoma xenograft model (ED50 = 2.6 mg/kg QD) and the HCT-116 colorectal carcinoma xenograft model (ED50 = 10 mg/kg QD). In addition, 25 possesses distinct mechanisms of elimination compared to 1.

Related Papers

• → Anticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2(2020)26 cited
• → Analgesic activities of PEM-420, the active eutomer of pemedolac(1993)13 cited
• → The relationship between morphine analgesia and the levels of biogenic amines in the mouse brain(1970)43 cited
• → Neuromuscular interactions between suxamethonium and magnesium sulphate in the cat(1994)13 cited
• The regulation of MDM2 oncogene and its impact on human cancers(2014)